Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Emisphere -- Ignore unavailable to you. Want to Upgrade?

To: Harold Engstrom who wrote (228)	10/28/2005 8:45:41 PM
From: Miljenko Zuanic	Read Replies (3) \| Respond to of 272

Hi Harold, Didn't follow emis for last +18 months (if not more), so can not be objective. Did they increase bioavailability of the heparin with new formulation? Heparin is too complex to prove (easily) that iv/sc dosing and oral formulation generate the same active molecule in blood stream. Second, there are better drugs on market than “old” heparin. The better chances are with insulin, but this program didn't move forward for last +5 years. The best chance is NVS calcitonic and small molecule formulation. However, royalty from NVS (unless OA indication is positive) may not be sufficient to turn them around into "serious" business. Miljenko